In summary, this BOOSTER study showed that the addition of LCT, thermal ablation or cryoablation, is well tolerated and leads to a clinically meaningful prolongation of PFS and OS compared with continuous immunotherapy alone in advanced NSCLC patients who develop ORD after anti-PD-1/PD-L1 therapy. Here, CD274 is linked to non-small cell lung carcinoma.